Entecavir
- Generic Name
- Entecavir
- Brand Names
- Baraclude, Entecavir Viatris (previously Entecavir Mylan), Entecavir Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C12H15N5O3
- CAS Number
- 142217-69-4
- Unique Ingredient Identifier
- NNU2O4609D
- Background
Entecavir is an oral antiviral drug used in the treatment of hepatitis B infection. It is marketed under the trade name Baraclude (BMS).
...
- Indication
For the treatment of chronic hepatitis B virus infection in adults with evidence of active viral replication and either evidence of persistent elevations in serum aminotransferases (ALT or AST) or histologically active disease.
- Associated Conditions
- Chronic Hepatitis B Infection
- Associated Therapies
- -
A Study of FG-3019 in Subjects With Liver Fibrosis Due to Chronic Hepatitis B Infection
- Conditions
- Interventions
- First Posted Date
- 2010-10-08
- Last Posted Date
- 2016-08-16
- Lead Sponsor
- FibroGen
- Target Recruit Count
- 114
- Registration Number
- NCT01217632
- Locations
- 🇭🇰
Ruttonjee Hospital, Wanchai, Hong Kong Island, Hong Kong
🇹🇭Siriraj Hospital, Siriaj, Bangkok Noi, Thailand
🇹🇭Maharaj Nakorn Chiang Mai Hospital, Amphur Muang, Chiang Mai, Thailand
Dose Ranging Study of Pegylated Interferon Lambda in Patients With Hepatitis B and Positive for the Hepatitis B e Antigen
- Conditions
- Interventions
- First Posted Date
- 2010-09-17
- Last Posted Date
- 2015-10-09
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 197
- Registration Number
- NCT01204762
- Locations
- 🇺🇸
Sc Clinical Research, Inc., Garden Grove, California, United States
🇺🇸Mercy Medical Center, Baltimore, Maryland, United States
🇺🇸Office Of Sing Chan Md, Flushing, New York, United States
A Study of 48 Versus 96 Weeks of Peginterferon Alfa-2a [Pegasys] Treatment, With or Without Entecavir, in Patients With Chronic Hepatitis B.
- Conditions
- Interventions
- First Posted Date
- 2010-08-11
- Last Posted Date
- 2017-02-17
- Lead Sponsor
- Hoffmann-La Roche
- Registration Number
- NCT01179594
Influence of Hepatic Steatosis on the Therapeutic Effect of Entecavir in Chronic Hepatitis B Patients
- Conditions
- Interventions
- First Posted Date
- 2010-06-22
- Last Posted Date
- 2010-06-22
- Lead Sponsor
- Zhejiang University
- Target Recruit Count
- 1200
- Registration Number
- NCT01148576
- Locations
- 🇨🇳
The first affiliated hospital, college of medicine, zhejiang university, Hangzhou, Zhejaing, China
A Phase III Study of the Safety and Efficacy of Entecavir in Pediatric Patients With Chronic Hepatitis B Virus Infection
- Conditions
- Interventions
- First Posted Date
- 2010-03-03
- Last Posted Date
- 2019-05-09
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 180
- Registration Number
- NCT01079806
- Locations
- 🇺🇸
Children'S National Medical Center, Washington, District of Columbia, United States
🇺🇸Shah, Uzma, Boston, Massachusetts, United States
🇺🇸Children'S Hospital Of Philadelphia, Philadelphia, Pennsylvania, United States
Efficacy and Safety Study of Entecavir Plus Tenofovir in Patients With Chronic Hepatitis B Who Failed Previous Treatment
- First Posted Date
- 2010-02-05
- Last Posted Date
- 2014-12-15
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 144
- Registration Number
- NCT01063036
- Locations
- 🇪🇸
Local Institution, Valencia, Spain
Prevention of Hepatitis B Virus Reinfection After Liver Transplantation With Entecavir
- First Posted Date
- 2010-01-12
- Last Posted Date
- 2014-11-05
- Lead Sponsor
- HepNet Study House, German Liverfoundation
- Target Recruit Count
- 20
- Registration Number
- NCT01046799
- Locations
- 🇩🇪
University Clinic Essen, Essen, Germany
🇩🇪Hannover Medical School, Hannover, Germany
🇩🇪University Hospital Heidelberg, Heidelberg, Germany
Study in Japan of the Safety And Antiviral Activity in Adults With Chronic Hepatitis B Current Lamivudine Therapy
- First Posted Date
- 2009-12-21
- Last Posted Date
- 2011-01-31
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 84
- Registration Number
- NCT01037166
- Locations
- 🇯🇵
Local Institution, Kyoto, Japan
An Open-Label Rollover Study of Entecavir (BMS-200475) in Adults With Chronic Hepatitis B Infection
- First Posted Date
- 2009-12-21
- Last Posted Date
- 2011-01-31
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 282
- Registration Number
- NCT01037062
- Locations
- 🇯🇵
Local Institution, Tokyo, Japan
Entecavir Plus Adefovir in Lamivudine-Resistant Chronic Hepatitis B Patients Who Fail Lamivudine Plus Adefovir
- Conditions
- Interventions
- First Posted Date
- 2009-12-02
- Last Posted Date
- 2014-02-10
- Lead Sponsor
- Asan Medical Center
- Target Recruit Count
- 90
- Registration Number
- NCT01023217
- Locations
- 🇰🇷
Asan Medical Center, Seoul, the Meteropolis of Seoul, Korea, Republic of
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.